PD1抑制剂-话题@MedSci

#PD1抑制剂#

8篇内容 | 1037人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2020116, encodeId=55f22020116d6, content=<a href='/topic/show?id=328713934ea' target=_blank style='color:#2F92EE;'>#PD1抑制剂#</a>, objectTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, objectType=article, longId=292494, objectId=9f45292494ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f45292494ff, replyNumber=0, likeNumber=88, createdTime=2022-07-19, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f45292494ff, moduleTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f45292494ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2020115, encodeId=756d202011588, content=<a href='/topic/show?id=328713934ea' target=_blank style='color:#2F92EE;'>#PD1抑制剂#</a>, objectTitle=PD1抑制剂逆转安罗替尼获得耐药性2例报道, objectType=article, longId=220698, objectId=39ca22069861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39ca22069861, replyNumber=0, likeNumber=94, createdTime=2022-01-19, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39ca22069861, moduleTitle=PD1抑制剂逆转安罗替尼获得耐药性2例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39ca22069861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2020113, encodeId=3fd6202011311, content=<a href='/topic/show?id=328713934ea' target=_blank style='color:#2F92EE;'>#PD1抑制剂#</a>, objectTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, objectType=article, longId=212747, objectId=5467212e47b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5467212e47b0, replyNumber=0, likeNumber=90, createdTime=2022-04-08, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5467212e47b0, moduleTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5467212e47b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2020111, encodeId=3ea5202011187, content=<a href='/topic/show?id=328713934ea' target=_blank style='color:#2F92EE;'>#PD1抑制剂#</a>, objectTitle=J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性, objectType=article, longId=211247, objectId=676f21124ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676f21124ed8, replyNumber=0, likeNumber=90, createdTime=2021-07-15, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676f21124ed8, moduleTitle=J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676f21124ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2020114, encodeId=013d20201145c, content=<a href='/topic/show?id=328713934ea' target=_blank style='color:#2F92EE;'>#PD1抑制剂#</a>, objectTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, objectType=article, longId=220048, objectId=533b22004862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=533b22004862, replyNumber=0, likeNumber=117, createdTime=2022-05-09, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=533b22004862, moduleTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=533b22004862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2020110, encodeId=5d6d2020110ed, content=<a href='/topic/show?id=328713934ea' target=_blank style='color:#2F92EE;'>#PD1抑制剂#</a>, objectTitle=未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择, objectType=article, longId=211116, objectId=6a65211116f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a65211116f9, replyNumber=0, likeNumber=86, createdTime=2021-11-26, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a65211116f9, moduleTitle=未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a65211116f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2020112, encodeId=505c20201124c, content=<a href='/topic/show?id=328713934ea' target=_blank style='color:#2F92EE;'>#PD1抑制剂#</a>, objectTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, objectType=article, longId=211606, objectId=ff0121160699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0121160699, replyNumber=0, likeNumber=88, createdTime=2021-08-29, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0121160699, moduleTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0121160699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2020109, encodeId=3e4920201093b, content=<a href='/topic/show?id=328713934ea' target=_blank style='color:#2F92EE;'>#PD1抑制剂#</a>, objectTitle=2018 意大利专家共识声明：优化PD1抑制剂治疗经典霍奇金淋巴瘤, objectType=article, longId=151689, objectId=b07d15168973, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b07d15168973, replyNumber=0, likeNumber=64, createdTime=2018-11-15, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b07d15168973, moduleTitle=2018 意大利专家共识声明：优化PD1抑制剂治疗经典霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b07d15168973)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD1抑制剂

2020-05-29

ms8543593053280928 (审核中...)

前往app查看评论内容

#PD1抑制剂#

Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用

2022-07-19

ms8543593053280928 (审核中...)

前往app查看评论内容

#PD1抑制剂#

PD1抑制剂逆转安罗替尼获得耐药性2例报道

2022-01-19

ms8543593053280928 (审核中...)

前往app查看评论内容

#PD1抑制剂#

J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性

2022-04-08

ms8543593053280928 (审核中...)

前往app查看评论内容

#PD1抑制剂#

J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性

2021-07-15

ms8543593053280928 (审核中...)

前往app查看评论内容

#PD1抑制剂#

Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性

2022-05-09

ms8543593053280928 (审核中...)

前往app查看评论内容

#PD1抑制剂#

未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择

2021-11-26

ms8543593053280928 (审核中...)

前往app查看评论内容

#PD1抑制剂#

Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估

2021-08-29

ms8543593053280928 (审核中...)

前往app查看评论内容

#PD1抑制剂#

2018 意大利专家共识声明：优化PD1抑制剂治疗经典霍奇金淋巴瘤

2018-11-15

科室
- - 订阅+
  - 更多科室
工具
服务